UNSPSC 51111750: Losoxantrone

This classification denotes an anthrapyrazole antibiotic with the molecular formula C22H27N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 47KPH00809, chemically known as anthra(1,9-cd)pyrazol-6(2h)-one, 7-hydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-((2-hydroxyethyl)amino)ethyl)amino)- but generally known as losoxantrone, which bears US NIH Compound Identifier 72116. European Medicines Agency schedules Losoxantrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08597MIG.

UNSPSC 51111750 Losoxantrone, a Commodity code, nominally covers a specific chemotherapy agent, but recent state and local solicitations under this code do not target losoxantrone procurement — instead they address a broader pharmaceutical and medical supply portfolio including naloxone, over-the-counter products, and generic multi-source pharmaceuticals. The code shows limited relevance to the work actually being solicited. State and local governments buying under this code are sourcing emergency medical supplies, pharmacy benefit program inputs, and community health support materials through county health departments, state pharmacy benefit agencies, fire departments, and cooperative purchasing alliances. Issuing bodies include Seminole County, Florida; the City of Tampa, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving state and local facilities across multiple jurisdictions.

Recent activity concentrates in Florida and the upper Midwest, with exploratory procurement in Texas. Representative solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026; due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually; the City of Tampa's IFB 26P00145 (posted March 25, 2026; due March 13, 2026) for 169 line items of medical and first aid supplies totaling an estimated $700,000 contract amount, designated as a sheltered market opportunity exclusively for certified Small Local Business Enterprises with a 5 percent bid discount; and MMCAP's RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across state and local government facilities in Minnesota and Oregon. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs. The mismatch between the code's nominal scope and recent solicitation content suggests the code is either miscoded in state and local systems or receives minimal relevant activity volume.